Defining a dose–response relationship for prostate external beam radiotherapy

Trada, Yuvnik; Plank, Ash; Martin, Jarad

doi:10.1111/1754-9485.12008

Cited by 19 publications

(17 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The estimated D 50 is significantly smaller than those of classical schemes. For the whole sample of studies, we [36]. This may be due (at least to some extent) to the shortening in the overall treatment time in HDR-BT schemes with respect to EBRT, which could produce an increase of the treatment effect for low-and intermediate-risk patients [37].…”

Section: Discussionmentioning

confidence: 98%

A radiobiological study of the schemes with a low number of fractions in high-dose-rate brachytherapy as monotherapy for prostate cancer

Guirado

Ruiz-Arrebola

Tornero-López

et al. 2020

jcb

View full text Add to dashboard Cite

Purpose: Schemes with high doses per fraction and small number of fractions are commonly used in high-dose-rate brachytherapy (HDR-BT) for prostate cancer. Our aim was to analyze the differences between published clinical results and the predictions of radiobiological models for absorbed dose required in a single fraction monotherapy HDR-BT. Material and methods: Published HDR-BT clinical results for low-and intermediate-risk patients with prostate cancer were revised. For 13 clinical studies with 16 fractionation schedules between 1 and 9 fractions, a dose-response relation in terms of the biochemical control probability (BC) was established using Monte Carlo-based statistical methods. Results: We obtained a value of α/β = 22.8 Gy (15.1-60.2 Gy) (95% CI) much larger than the values in the range 1.5-3.0 Gy that are usually considered to compare the results of different fractionation schemes in prostate cancer radiotherapy using doses per fraction below 6 Gy. The doses in a single fraction producing BC = 90% and 95% were 22.3 Gy (21.5-24.2 Gy) and 24.3 Gy (23.0-27.9 Gy), respectively. Conclusions: The α/β obtained in our analysis of 22.8 Gy for a range of dose per fraction between 6 and 20.5 Gy was much greater than the one currently estimated for prostate cancer using low doses per fraction. This high value of α/β explains reasonably well the data available in the region of high doses per fraction considered.

show abstract

Section: Discussionmentioning

confidence: 98%

A radiobiological study of the schemes with a low number of fractions in high-dose-rate brachytherapy as monotherapy for prostate cancer

Guirado

Ruiz-Arrebola

Tornero-López

et al. 2020

jcb

View full text Add to dashboard Cite

show abstract

“…The total dose is usually delivered in multiple smaller fractions of, for example, 2 Gy per day for 60 days, not including weekends [61]. Following treatment, patients may often experience side effects including but not limited to urinary incontinence, diarrhoea, and rectal discomfort.…”

Section: Approaches To Focal Therapy Of Localized Prostate Cancermentioning

confidence: 99%

Low Temperature Plasma: A Novel Focal Therapy for Localized Prostate Cancer?

Hirst

Frame

Maitland

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Despite considerable advances in recent years for the focal treatment of localized prostate cancer, high recurrence rates and detrimental side effects are still a cause for concern. In this review, we compare current focal therapies to a potentially novel approach for the treatment of early onset prostate cancer: low temperature plasma. The rapidly evolving plasma technology has the potential to deliver a wide range of promising medical applications via the delivery of plasma-induced reactive oxygen and nitrogen species. Studies assessing the effect of low temperature plasma on cell lines and xenografts have demonstrated DNA damage leading to apoptosis and reduction in cell viability. However, there have been no studies on prostate cancer, which is an obvious candidate for this novel therapy. We present here the potential of low temperature plasma as a focal therapy for prostate cancer.

show abstract

“…According to profile matching based on clinical characteristics, our study patients are comparable to intermediate-risk patients treated with radiotherapy and without hormone therapy as in the study of Heemsbergen et al [20]. Therefore, consistent with the outcome of these patients [20,21], we first calibrated the a and b values so that 80% TCP would be reached in our patient cohort with a conventional dose of 78 Gy in 2 Gy fractions. The a/b value was set to 1.93 Gy [22].…”

Section: Tumor Control Probabilitymentioning

confidence: 84%

Histopathology-derived modeling of prostate cancer tumor control probability: Implications for the dose to the tumor and the gland

Ghobadi

Jong

Hollmann

et al. 2016

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

Defining a dose–response relationship for prostate external beam radiotherapy

Abstract: A strong association was found between radiation dose and biochemical outcome in both low- and intermediate-risk patients. Standardised reporting of results from future studies will make future analyses more robust.

Cited by 19 publications

References 45 publications

A radiobiological study of the schemes with a low number of fractions in high-dose-rate brachytherapy as monotherapy for prostate cancer

A radiobiological study of the schemes with a low number of fractions in high-dose-rate brachytherapy as monotherapy for prostate cancer

Low Temperature Plasma: A Novel Focal Therapy for Localized Prostate Cancer?

Histopathology-derived modeling of prostate cancer tumor control probability: Implications for the dose to the tumor and the gland

Contact Info

Product

Resources

About